56 results about "Brain trauma" patented technology

Safety head wear for use for example in high risk activities such as sports and industrial purposes where protection from head injuries is required. Components are provided inserted between the liner and outer shell and consists of two parts; a chamber or bladder and a fluid or gel like material. The fluid or gel material is contained in the chamber or bladder and is positioned in such a way to create low friction between the surface of the shell and liner or liner and head. It can also be used on the outer surface of the shell or placed within two layers of the liner. The device provides a method of independently managing both compression and shear force characteristics of the helmet around the head designed to decrease brain trauma resulting from high linear and angular acceleration during impacts to the helmet.

The embodiment of the invention provides a hemiplegia risk prediction method and system suitable for a brain trauma patient. The method comprises the following steps: acquiring patient information and medical data of the brain trauma patient uploaded by different medical nodes; screening high-risk patients with hemiplegia through the comprehensive risk assessment scores; constructing and pre-training a hemiplegia prediction model to obtain a hemiplegia risk score of the brain trauma patient; the hemiplegia risk score is automatically evaluated and recorded through the first intelligent contract, early warning is triggered according to a preset risk threshold value, early warning information is sent to the medical node and the patient, and updating and recording of the hemiplegia prediction model are automatically triggered through the second intelligent contract. According to the method, the risk score is calculated by comprehensively utilizing the hemiplegia symptom keyword and the dynamic physiological index, early screening of the hemiplegia high-risk patient is achieved, accurate risk prediction and automatic early warning of the image data are achieved based on the prediction model, and the timeliness of hemiplegia risk intervention of the brain trauma patient is improved.

The invention relates to the technical field of medicine, in particular to application of an Acp5 inhibitor in cerebral edema after traumatic brain trauma, and the Acp5 inhibitor comprises a medicine with the ACP5 inhibitor as an active component and a prodrug form of the medicine. According to the invention, through an enzyme-substrate key activation mechanism, a drug is coupled by using an ACP5 specific substrate peptide, dual response release is realized in a lesion area, and the targeting property and the safety are remarkably improved. The prodrug is composed of a core inhibitor module, an ACP5 substrate peptide module and a pH response connection module, and can accurately inhibit ACP5 + macrophage infiltration and reduce encephaledema volume and neuroinflammation. The application can effectively treat acute and chronic encephaledema, reduce off-target effect and side effect, and provide a brand new treatment strategy for traumatic brain trauma.

The present invention belongs to the technical field of medicine. Disclosed are a class of magnolol / honokiol derivatives, a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention are magnolol / honokiol nitrone derivatives as represented by general formulas (I) and (II). Such derivatives are prepared by means of artificial synthesis. Further provided are a pharmaceutical composition containing same, and the use thereof against inflammation, against cerebral infarction, in the treatment of amyotrophic lateral sclerosis, and against cerebral trauma.

The invention is applicable to the field of brain-computer interfaces and rehabilitation medicine, and provides a brain injury function training device based on a brain-computer interface, which comprises a support frame, an electroencephalogram acquisition module, a signal processing module, a training control module, a feedback module, an evaluation module and a user interaction module, in the first stage, accurate collection and preprocessing of electroencephalogram signals are achieved through a flexible electrode array and a low-noise amplification and self-adaptive noise reduction technology; secondly, through linkage of an evaluation module and a training control module, dynamic optimization of a personalized training scheme is achieved; thirdly, constructing a visual, auditory and tactile multi-mode feedback and quantitative evaluation closed loop; according to the brain injury function training device, the problems that an existing device is low in electroencephalogram signal collection precision, fixed in training scheme and lack of a training-evaluation-adjustment closed loop are solved, the accuracy, adaptability and user participation degree of brain injury function training are improved, and the brain injury function training device is suitable for function recovery training of movement, cognition, language and the like of brain injury patients with cerebral apoplexy, cerebral trauma and the like.

The present invention discloses a preparation method of rhein / berberine / glycyrrhizic acid hydrogel, which comprises the following steps: dispersing the rhein / berberine nanoparticle solution, glycyrrhizic acid and PBS solution uniformly, and standing to obtain the rhein / berberine / glycyrrhizic acid hydrogel; the concentration of glycyrrhizic acid in the hydrogel is 0.01-0.04 g / mL. The rhein / berberine / glycyrrhizic acid hydrogel prepared by the present invention has the characteristics of anti-inflammation, reducing edema, neuroprotection, etc., solves the limitation of poor curative effect of single-component drugs, realizes in-situ injection administration of three small-molecule drugs, and has synergistic effect, and is applied in drugs for treating inflammatory or edematous encephalopathy accompanied by traumatic brain injury, cerebral edema, Alzheimer's disease, Parkinson's disease, etc., and has obvious therapeutic effect.

The invention discloses a 2-(piperidinyl) pyridazinone compound (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-(piperidinyl) pyridazinone compound, a pharmaceutical composition of the 2-(piperidinyl) pyridazinone compound and application of the 2-(piperidinyl) pyridazinone compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

The present invention relates to the field of medicine, and specifically to the use of taraxasterol or its salts in the preparation of drugs for preventing or treating traumatic brain injury. Animal experiments have confirmed that the taraxasterol of the present invention can improve the motor ability of the balance beam experiment in the neurological function score of mice with brain trauma, improve the neurological function scores including motor tests and sensory tests; reduce the permeability of the blood-brain barrier, reduce brain edema, improve the short-term lesion volume after traumatic brain injury, and inhibit microglial activation and immune cell infiltration. Cytological experiments have confirmed that taraxasterol can reduce microglia-mediated neuroinflammation, reduce the expression of inflammatory factors such as TNF-α, IL-6, and IL-1β, and reduce neuronal damage.

The invention discloses ursodesoxycholic acid and amino acid conjugates (I), pharmaceutically acceptable salts thereof, a preparation method of the ursodesoxycholic acid and amino acid conjugates, a pharmaceutical composition of the ursodesoxycholic acid and amino acid conjugates and application of the ursodesoxycholic acid and amino acid conjugates in preparation of drugs for treating and / or preventing comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The invention discloses application of a gene editing virus interfering expression and secretion of enzyme prototype cathepsin D in brain trauma, belongs to the field of gene functions and application, and finds that brain injury is aggravated and nerve dysfunction is aggravated due to the fact that the level of the enzyme prototype cathepsin D in plasma is increased due to the brain trauma through detection. The mechanism is as follows: the enzyme prototype cathepsin D enhances the transendocytosis effect of cerebral vascular endothelial cells after brain trauma, so that plasma inflammatory factors are gathered in damaged brain tissues; meanwhile, the expression of cerebrovascular endothelial cells VCAM-1 is also up-regulated, and neutrophil infiltration in an injured brain region after brain trauma is intensified. Research finds that down-regulation of plasma enzyme prototype cathepsin D can alleviate inflammatory factor concentration and neutrophil density in a brain injury area after trauma, and alleviate neurological function impairment of mice. Aiming at the functions of the plasma prototype cathepsin D, a strategy for reducing the plasma level of the plasma prototype cathepsin D by a gene editing technology for interfering the prototype cathepsin D is provided for treating the cerebral trauma.

The invention discloses an aminoamide alkyl thioester compound (I), pharmaceutically acceptable salts thereof, a preparation method of the aminoamide alkyl thioester compound, a pharmaceutical composition of the aminoamide alkyl thioester compound and application of the aminoamide alkyl thioester compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The invention discloses an amide alkyl thiol ester compound (I) as well as a preparation method and a pharmaceutical composition thereof, and application of the amide alkyl thiol ester compound in preparation of drugs for treating and / or preventing diseases by resisting oxidative stress, inhibiting amyloid protein aggregation and resisting neuroinflammation. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The invention belongs to the technical field of biological medicines, and provides application of sodium tyrosol sulfate and a derivative tyrosol compound in preparation of brain health products. The structure of the sodium tyrosol sulfate and the derivative tyrosol compound is shown as a formula I. The sodium tyrosol sulfate and the derivative tyrosol compound can effectively reduce the infarction area after cerebral ischemia and relieve encephaledema caused by cerebral ischemia, and have wide application in the aspects of resisting cerebral ischemia and improving encephaledema and cerebral infarction caused by cerebral ischemia. Meanwhile, learning and memory abilities can be effectively improved, brain function recovery is promoted, and the traditional Chinese medicine composition can be widely applied to treatment of behavior / cognitive dysfunction diseases such as cerebral trauma, cerebrovascular accidents, Alzheimer's disease and Parkinson's disease. And the formula I of the # imgabs0 # is shown in the specification.

The present invention relates to the use of 3,4-dihydro-2H-benzo-[1,4]oxazine drugs or salts thereof in the preparation of drugs for inhibiting ferroptosis, in particular to the use of 3,4-dihydro-2H-benzo-[1,4]oxazine compounds or salts thereof in the preparation of drugs for treating ferroptosis-related diseases, wherein the ferroptosis-related diseases include brain trauma, stroke, cardiovascular disease, liver and kidney failure, inflammation and neurodegenerative diseases, such as Parkinson's disease and schizophrenia.

This invention discloses a system, method, and device that provides magnetic transcranial stimulation to establish new or adjust existing neuron activities in targeted zones within the brain. This invention corrects neurological pathways that have been damaged, or have dysfunctional neurological systems such as autism, delayed development, and brain trauma, etc. The therapies available using this invention This improved therapy consists primarily of transcranial stimulation (TCS) with precisely targeted magnetic waves rapidly rotating to establish the desired paths of activation. The devices and methods disclosed herein rapidly and painlessly deliver magnetic pulses through the skull to electrically stimulate nerve cells in one or more targeted regions in the brain. The induced electrical activities cause the brain to respond and activate selected cellular pathways in regions of the brain.

The invention discloses a brain trauma postoperative recovery evaluation system based on artificial intelligence, which combines artificial intelligence and medical technology and provides an innovative scheme for postoperative recovery evaluation of a brain trauma patient. By collecting and analyzing medical images, physiological parameters and other multi-dimensional data, a prediction model is constructed by using LSTM and other advanced algorithms, and the recovery degree and speed of a patient are accurately evaluated; the system can automatically generate a personalized rehabilitation plan, dynamically adjust according to the rehabilitation progress, provide a visual evaluation report and a rehabilitation curve chart, and enhance doctor decision support and patient participation. Compared with a traditional evaluation method, the system significantly improves the evaluation accuracy and efficiency, reduces the workload of doctors, and improves the rehabilitation effect and life quality of patients. Meanwhile, innovation and development of medical technologies are promoted, new vitality is injected into the field of postoperative recovery evaluation of cerebral trauma, formulation of industrial standards and specifications is expected to be guided, and improvement of the overall level of the medical field is promoted.

The invention provides a cerebral trauma segmentation method based on deep semantic fusion, and the method comprises the steps: obtaining traumatic brain injury tissue data, and carrying out the preprocessing of sample data; designing a semantic coding module, and extracting semantic features of the sample data; a semantic segmentation module is designed to complete a semantic segmentation task, and an image fusion module is designed to assist semantic segmentation, so that the segmentation accuracy is improved; segmenting the region to be segmented; according to the method, depth semantic information of different modals in MRI is fused, the wound penumbra and the injury core area can be accurately segmented, the accuracy of the segmentation result is ensured, the use method is simple, the method has the advantages of being easy to implement, small in calculation amount and low in data size requirement, meanwhile, a method based on the same variance uncertainty is introduced, and the method has good application prospects. The weights of different modules are dynamically adjusted, so that the accuracy of model segmentation is improved.

This invention relates to the pharmaceutical field, specifically to the application of tissue inhibitor metalloproteinases-2 (TIMP2) in the preparation of drugs for the prevention or treatment of traumatic brain injury. TIMP2 protein can increase the fall latency in rotarod experiments in mice with traumatic brain injury; improve the motor balance ability of mice with traumatic brain injury on a balance beam; improve neurological function impairment in mice with traumatic brain injury; and reduce Evans blue permeability in brain tissue. In brain microvascular endothelial cells (HBMECs), TIMP2 protein can participate in maintaining the integrity of the endothelial barrier, reversing the loss of expression and altered localization of the connectome complex induced in an in vitro traumatic brain injury model, and reducing luciferase leakage. This invention also provides the application of TIMP2 protein as an Integrin α3β1 ligand in the preparation of drugs for the treatment of central nervous system diseases caused by blood-brain barrier dysfunction. TIMP2 protein exerts its function by binding to the cell membrane receptor Integrin α3β1, regulating VE-Cadherin phosphorylation. TIMP2 protein shows promising application prospects in the treatment of blood-brain barrier dysfunction caused by traumatic brain injury.

The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

This invention belongs to the field of pharmaceutical application technology, specifically relating to a folic acid derivative, its preparation method, and its application in preventing and treating ferroptosis. The folic acid derivative of this invention comprises compounds represented by general formula (I) and their pharmaceutically acceptable salts. The folic acid compounds provided by this invention, by introducing a lipophilic group or a specific group at the R position, yield compounds with good ferroptosis inhibitory activity, which can be used to treat non-alcoholic steatohepatitis, acute liver injury, cardiomyopathy, drug-induced cardiotoxicity, atherosclerosis, acute kidney injury, renal fibrosis, pneumonia, preeclampsia, osteoporosis, osteoarthritis, traumatic brain injury, and neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and epilepsy.

A method for treating low-level blast traumatic brain injury includes administering a phosphodiesterase-5 (PDE5) inhibitor, such as sildenafil, to a subject following exposure of the subject to one or more low-level blasts. Administration of the PDE5 inhibitor may prove useful with respect to improving the vascular integrity of a subject by increasing brain capillary respiration, mitochondrial respiration, mitochondrial density, mitochondrial biogenesis, astrocyte level or homeostasis, and / or tight junction protein expression in the brain of the subject and / or inducing positive metabolic change in the subject by increasing NAD+ / NADH metabolism. Methods for mitigating the effects of blast injury on the vascular integrity of a subject and inducing metabolic change are also provided.

The invention provides a cerebral trauma semi-dark band image segmentation method and device, equipment, a medium and a product, and the method comprises the steps: obtaining at least two modal magnetic resonance images, inputting the at least two modal magnetic resonance images into a trained feature fusion module for fusion, and obtaining a fusion image; and inputting the fused image into a trained segmentation module for image segmentation to obtain a cerebral trauma semi-dark band region. According to the invention, the automatic identification of the cerebral trauma penumbra region is realized, and the identification efficiency of the cerebral trauma penumbra region is improved.

The invention belongs to the technical field of medical treatment, and relates to a method for constructing an animal traumatic brain injury model based on low-intensity pulsed ultrasound regulation and application thereof. The method comprises the following steps: (1) establishing a TBI mouse by adopting controlled cortical injury so as to simulate neurological impairment caused by open brain trauma; (2) setting low-intensity pulse ultrasonic conditions, and performing low-intensity pulse ultrasonic treatment on the TBI mouse; and (3) comparing the influence of the space learning and long-term memory ability of the TBI mouse before and after the low-intensity pulsed ultrasound treatment and the change of the intracerebral clearance ability, and detecting the level of phosphorylated tau protein in the damaged cerebral hemisphere, if the influence on the TBI mouse has statistical significance, judging that the TBI mouse is damaged by the phosphorylated tau protein. And if not, constructing a low-intensity pulsed ultrasound regulation animal traumatic brain injury model by using the low-intensity pulsed ultrasound condition. By regulating and controlling the key parameters of the low-intensity pulsed ultrasound, the brain lymphatic drainage and nerve repair of traumatic brain injury of animals can be regulated and controlled.

The invention provides an artificial dura mater material as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. Aiming at the defects of the traditional artificially synthesized dura mater (spinal mater), the artificial dura mater (spinal mater) is processed by adopting the poly L-lactide-caprolactone (PLCL), adding the RAPA with a specific concentration and adopting an electrostatic spinning process, has the characteristics of low porosity and compact texture, and induces the rapid endothelialization of the dura mater in the early stage of craniocerebral trauma, and then, along with the release of the RAPA, the porosity of the material is increased, so that the endothelialization of the dura mater (spinal mater) in the early stage of craniocerebral trauma is improved. And proliferation and growth of new dura mater cells are facilitated. Meanwhile, the RAPA can prevent excessive proliferation of new endothelium and scar hyperplasia. Pathological proliferation can be selectively inhibited without damaging necessary lymphatic drainage; while the physical structure integrity of the dura mater is maintained, the nerve function repair can be promoted.

The utility model discloses a multi-degree-of-freedom rehabilitation training device applied to ankle joints, which comprises an xy plane deflection structure, an xz plane deflection structure and a yz plane deflection structure which are respectively driven by a first motor, a second motor and a third motor, and a pedal fixer is arranged on the yz plane deflection structure. The xy plane deflection structure comprises a base, a rotary table and a first transmission assembly. The xz plane deflection structure comprises a hollow shell with an arc-shaped bottom shell and a second transmission assembly; the yz plane deflection structure comprises a pedal bearing plate and a third transmission assembly. Each transmission assembly comprises a precise transmission element, and stable operation is ensured. The device is based on motion bionics, cooperates with a three-plane deflection structure, simulates ankle joint movement, achieves various training actions of ankles, and enhances strength, flexibility and stability. The device is especially suitable for training of ankle joint dyskinesia caused by cerebral apoplexy, cerebral trauma, spinal cord injury and the like.

The invention discloses 2-sulfur-3-(piperidinedithio) phthalide (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-sulfur-3-(piperidinedithio) phthalide (I), a pharmaceutical composition of the 2-sulfur-3-(piperidinedithio) phthalide (I) and application of the 2-sulfur-3-(piperidinedithio) phthalide (I) in preparation of drugs for treating and comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

This invention provides an artificial dura mater material, its preparation method, and its applications, belonging to the field of biomedical technology. Addressing the shortcomings of traditional synthetic dura mater, this invention utilizes poly(L-lactide-caprolactone) (PLCL) with a specific concentration of RAPA, processed using electrospinning. It exhibits low porosity and a dense texture, inducing rapid endothelialization of the dura mater in the early stages of traumatic brain injury. Subsequently, with the release of RAPA, the material's porosity increases, facilitating the proliferation and growth of newly formed dura mater cells. Simultaneously, RAPA can prevent excessive proliferation of new endothelial cells and scar hyperplasia. It can selectively inhibit pathological proliferation without impairing necessary lymphatic drainage; while maintaining the physical structural integrity of the dura mater, it can promote neurological function repair.

This utility model relates to the field of rehabilitation training devices, and particularly to a rehabilitation training device for promoting awakening in patients with severe traumatic brain injury and persistent coma. It includes a bed frame, with a pillow fixedly connected to the upper rear part of the bed frame. A first arm movement device is movably connected to the left rear part of the bed frame, and a second arm movement device is movably connected to the right rear part of the bed frame. This rehabilitation training device for patients with severe traumatic brain injury and persistent coma utilizes the first arm movement device. The patient's arm is placed within a first and second support plate, and the arm is restrained by straps. When a motor is activated, it drives a transmission rod to rotate, which in turn rotates a connecting block and the first support plate on its right side. This allows the first and second support plates to reciprocate at different angles, thereby enabling the patient's arm to move and facilitating awakening and rehabilitation.

The invention discloses a multi-modal fusion portable cerebral trauma first-aid navigation system and method, and relates to the technical field of cerebral trauma first-aid navigation. The system comprises a handheld navigation device, a data acquisition module, a pose resolving module, a feature extraction module and a boundary recognition module. The handheld navigation equipment integrates a miniature ultrasonic probe and a 9-axis inertial measurement unit, a data acquisition module synchronously acquires intracranial ultrasonic echo sequence data and spatial motion parameters, and a pose resolving module resolves the spatial motion parameters in real time to determine real-time spatial pose data of the equipment in a head coordinate system. The feature extraction module inputs the ultrasonic echo sequence data into a pre-trained convolutional neural network model to output a multi-scale ultrasonic feature vector, and the boundary recognition module generates hematoma boundary dynamic labeling information in combination with the multi-scale ultrasonic feature vector and the real-time spatial pose data. The system is suitable for scenes of on-site first aid, patient transfer and the like, and assists medical staff in mastering the intracranial hematoma condition.

The present invention discloses a class of 3-benzyloxy-6-pyridylpyridazine compounds (I) and pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition thereof, and use thereof in preparing a drug for treating and / or preventing diseases by inhibiting monoamine oxidase B, metal ion complexation, or anti-neuroinflammation, including but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, prion disease, Lewy body dementia, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, ischemic stroke, hemorrhagic stroke, and nerve damage caused by brain trauma; #imgabs0#